Preclinical toxicological study of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in synergic ratio
Combination therapy between paclitaxel (PTX) and doxorubicin (DXR) is applied as the first-line treatment of breast cancer. Co-administration of drugs at synergistic ratio for treatment is facilitated with the use of nanocarriers, such as liposomes. However, despite the high response rate of solid t...
Guardado en:
Autores principales: | Marjorie Coimbra Roque, Caroline Dohanik da Silva, Marthin Raboch Lempek, Geovanni Dantas Cassali, André Luís Branco de Barros, Marília Martins Melo, Mônica Cristina Oliveira |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6877ad28e1be4f4dab58f15d3bd95e47 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac
por: Sudha T, et al.
Publicado: (2017) -
Development of paclitaxel-loaded liposomal nanocarrier stabilized by triglyceride incorporation
por: Hong SS, et al.
Publicado: (2016) -
Enhanced delivery of paclitaxel liposomes using focused ultrasound with microbubbles for treating nude mice bearing intracranial glioblastoma xenografts
por: Shen Y, et al.
Publicado: (2017) -
Improving the anti-keloid outcomes through liposomes loading paclitaxel–cholesterol complexes
por: Wang MJ, et al.
Publicado: (2019) -
Application of a lipid-coated hollow calcium phosphate nanoparticle in synergistic co-delivery of doxorubicin and paclitaxel for the treatment of human lung cancer A549 cells
por: Wu C, et al.
Publicado: (2017)